Umesolerbart Biosimilar Monoclonal Antibody (Bet v 1) for Research

Cat No.: GMP-Bios-INN-1438

Anti-Bet v 1 therapeutic antibody (Pre-made Umesolerbart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Umesolerbart (development codes REGN5713-5714-5715 (combination of Atisnolerbart/Bremzalerbart) is a monoclonal antibody targeting Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. It is developed by Regeneron for Allergic rhinitis, Birch pollen allergy in Phase III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1438-1mg 1mg 3090
GMP-Bios-INN-1438-10mg 10mg
GMP-Bios-INN-1438-100mg 100mg
GMP-Bios-INN-1438-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Umesolerbart biosimilar, Whole mAb: Anti-Bet v 1 therapeutic antibody
INN Name Umesolerbart
Target Bet v 1
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-III
Est. Status Active
100% SI Structure 7mxl:HL
99% SI Structure None
95-98% SI Structure None
Year Proposed 2022
Year Recommended 2023
Companies Regeneron
Conditions Approved na
Conditions Active Allergic rhinitis;Birch pollen allergy
Conditions Discontinued na
Production na
Development Tech na